Antoine Papiernik is a Managing Partner at Sofinnova Partners, which he joined in 1997. Antoine Papiernik has been an Initial Investor and active Board Member in public companies like Actelion, Auris, ProQR, NovusPharma (then sold to CTI), Movetis (then sold to Shire), Mainstay, Pixium Vision and Stentys, which went public respectively on the Zürich stock exchange, the NASDAQ, the Milan Nuovo Mercato, the Belgium Stock Exchange, the Dublin Stock Exchange and EuroNext Paris, in Cotherix (initially NASDAQ listed, then sold to Actelion), CoreValve (sold to Medtronic), Fovea (sold to Sanofi Aventis) and Ethical Oncology Science (EOS, sold to Clovis Oncology).
He has also invested in and is a Board Member of private companies ReCor, MD Start, Shockwave Medical, and Reflexion Medical and ProQR. Antoine Papiernik has an MBA from the Wharton School of Business, University of Pennsylvania. In 2012 and 2011, he was selected by Forbes for its “Midas List” of the world’s top venture capital investors. Antoine Papiernik is one of the only Europeans on the list, and one of the few life science investors as well.